The Fourth Wave: A New Generation of Protein-Based Therapeutics

Table of Contents

• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• Introduction
• Current Landscape of Recombinant Protein and MAb Therapeutics
• The Protein Therapeutic Market
• Key Players in the Protein Therapeutic Marketplace
• First-Generation Protein Therapeutics
• Sidebar: Monoclonal Antibodies: An Important Class of Protein Therapeutics
• The Changing Landscape: Opportunities for Second-Generation Protein Therapeutics
• New Approaches in Developing Next-Generation Protein Therapeutics
• Increasing Affinity
• Targeting Therapeutics with Fusion Proteins
• Improving Potency Through Cytotoxicity
• Engineering Constant Regions
• Conjugated Protein Therapeutics .
• Reducing Immunogenicity
• Protein Production
• Corporate Profiles
• Affibody
• Ambrx
• Chromos Molecular Systems
• EvoGenix
• Seattle Genetics
• Trellis Bioscience
• Outlook for Protein Therapeutics

Tables

• 1. Marketed MAb Therapeutics
• 2. Recent Acquisitions in Proteins and MAbs
• 3. Select Companies in Protein/MAb Engineering/Production

Figures

• 1. Protein Therapeutic Market, 2005 and 2010
  • A. Structural Components of an IgG Antibody
  • B. Antibodies: From Mouse to Human